GLPwatch
Papers (12034)
Page 24 of 201, ranked by citation count.
- Semaglutide in Early Type 1 Diabetes.
- Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes.
- Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.
- Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes.
- Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: A pilot study.
- Long acting hyaluronate--exendin 4 conjugate for the treatment of type 2 diabetes.
- Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction.
- An overview of the pharmacokinetics, efficacy and safety of liraglutide.
- Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes.
- Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data.
- Glucagon-Like Peptide 1 and Its Cleavage Products Are Renoprotective in Murine Diabetic Nephropathy.
- Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues-Liraglutide and Semaglutide.
- Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings.
- Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
- Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss.
- GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK.
- The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial.
- Fc-modified exenatide-loaded nanoparticles for oral delivery to improve hypoglycemic effects in mice.
- One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice.
- Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis.
- Activation of glucagon-like peptide-1 receptor in microglia attenuates neuroinflammation-induced glial scarring via rescuing Arf and Rho GAP adapter protein 3 expressions after nerve injury.
- Novel GLP-1 receptor agonists for diabetes.
- Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes.
- Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.
- Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
- Effects of the GLP-1 Agonist Exendin-4 on Intravenous Ethanol Self-Administration in Mice.
- A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes.
- Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats.
- AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists.
- Glucagon-Like Peptide-1 Receptor Agonist Treatment Does Not Reduce Abuse-Related Effects of Opioid Drugs.
- Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis.
- Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates.
- Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists.
- Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes.
- Hypoglycemic medicines in the treatment of Alzheimer's disease: Pathophysiological links between AD and glucose metabolism.
- Exendin-4 Ameliorates Lipotoxicity-induced Glomerular Endothelial Cell Injury by Improving ABC Transporter A1-mediated Cholesterol Efflux in Diabetic apoE Knockout Mice.
- Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting.
- Glucagon-Like Peptide-1 Receptor Agonism Improves Nephrotoxic Serum Nephritis by Inhibiting T-Cell Proliferation.
- Cardiovascular outcome trials of glucose-lowering medications: an update.
- Anti-inflammatory properties of exenatide in human pancreatic islets.
- GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1β-induced metabolic disturbance and mitochondrial dysfunction.
- Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial.
- 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study.
- Interventions for Weight Management in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
- The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies.
- Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada.
- Semaglutide in Adults with Type 1 Diabetes and Obesity.
- The glucagon-like peptide-1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis.
- Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome.
- Enteroendocrine cell regulation of the gut-brain axis.
- Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.
- Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial.
- Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders.
- Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist.
- The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study.
- The role of glia in the physiology and pharmacology of glucagon-like peptide-1: implications for obesity, diabetes, neurodegeneration and glaucoma.
- Liraglutide Attenuates Hepatic Ischemia-Reperfusion Injury by Modulating Macrophage Polarization.
- Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.
- Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial.
- Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy.